
|Videos|April 17, 2017
Dr. Janni on Challenges Facing the Treatment of HER2-Positive Breast Cancer
Author(s)Wolfgang Janni, MD, PhD
Wolfgang Janni, MD, PhD, University of Ulm, discusses challenges facing the treatment options for patients HER2-positive breast cancer.
Advertisement
Wolfgang Janni, MD, PhD, University of Ulm, discusses challenges facing the treatment options for patients HER2-positive breast cancer.
One of the challenges facing patients with HER2-positive breast cancer is determining the right treatment options for each specific patient. There is a strong standard therapy for metastatic breast cancer in the first-line setting, however, further investigation is also needed in later lines of treatment, explains Janni.
In the adjuvant setting, it is unsure what the right treatment will be and which patients will experience the best response, states Janni.
Advertisement
Advertisement
Advertisement
Trending on OncLive
1
ctDNA Status Has Strong Prognostic Value, Outperforming pCR Status, in Early TNBC
2
Antibody-Drug Conjugates in Lung Cancer: The Tip of the Iceberg
3
Retrospective Data Show Zanubrutinib May Less AFib Burden in Real-World CLL
4
Dato-DXd Hits Key Secondary Efficacy End Points in First-Line TNBC
5





























































